Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...
Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. The company also recently announced a partnership with Walmart that will expand access to Zepbound ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly and Company and Walmart Inc. today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...
Pharmaceutical company Novo Nordisk is working on an Ozempic-style semaglutide tablet just for weight loss, and early results ...
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...
Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback